Antimicrobial Resistance (AMR) Research Capital Funding

Status:  Open to applications

Application Deadline: 06 December 2018


Funding available to support capital investment in buildings (including refurbishment) and/or equipment to strengthen UK-based capacity and capability in AMR research.


Fund Value: £ 32,000,000
Maximum Value: £ 6,000,000
Minimum Value: £ 1,000,000

Value Notes

A total of £32 million is available.

NIHR expect the applications to be in the range of £1 million to £6 million and for the capital component to be the large majority of the cost.

Funding will be awarded for a two-year period starting on 1 April 2019. All funding provided to successful applicants must be spent by 31 March 2021.

Extended Description

Resistance to all antimicrobials, and especially bacterial resistance to existing antibiotics, is increasing. It is now posing a serious threat to health both in the United Kingdom (UK) and globally and risks undermining the major improvements in medicine that have been experienced in recent decades.

In response to this public health challenge and on behalf of the Department for Health and Social Care (DHSC), the National Institute for Health Research (NIHR) is providing funding through the Antimicrobial Resistance (AMR) Research Capital Fund. The funding aims to support an environment where scientific endeavour can thrive, attract the foremost talent and leverage additional investment by providing funding to support capital investment in buildings (including refurbishment) and/or equipment to strengthen UK-based capacity and capability in AMR research.

The purpose of AMR research capital funding is to provide research facilities and/or equipment to support AMR research to:

  • Foster innovative approaches to tackling AMR
  • Develop a cadre of researchers with a breadth of skills and expertise relevant to AMR
  • Leverage external funding to undertake AMR research
  • Translate novel or existing approaches to managing AMR into benefits for patients and public health.

Applications for funding to support research in the following research areas are invited:

  • Infection Prevention and Control: development of novel Infection Prevention and Control (IPC) interventions to prevent and reduce infections, and in particular Gram-negative bacterial infections, in health and care settings; generation of evidence to evaluate and determine effectiveness of new and existing IPC interventions, including changes to the built environment and interventions that promote behaviour change.
  • Novel interventions to prevent and treat healthcare-associated infections and infectious disease (except HIV and tuberculosis): approaches to prevent and manage infections other than by antimicrobials, for example, through manipulating the microbiome; immunotherapies; phage therapy; vaccines.
  • Effective use of current antimicrobials: dosing studies of antimicrobials (pharmacokinetics, pharmacodynamics); combination and/or repurposing of older antibiotics or other drugs.
  • Diagnostics: uptake and use of rapid diagnostics (including point-of-care) in primary and secondary care to support appropriate antibiotic prescribing. This may include building connectivity for point-of-care diagnostics that links in with lab data through automated digital reporting flows. (Note: early stage development of new diagnostic approaches is out of scope).

Latest Information

The deadline for applications is 6 December 2018.                                

Key Criteria

All NHS Trusts, Higher Education Institutions and not-for-profit UK research organisations (including the NHS and public sector agencies and research establishments) within the UK are eligible to apply.

Only a single application can be submitted by each organisation/ institution (in partnership or on their own). Partnership/collaborative applications are welcome; however, the funding for each application will be awarded to the lead organisation/ institution.

Eligible Expenditure

Up to £32 million is available to support capital (buildings (including refurbishment) and/or equipment), any associated costs, and associated project start-up costs. Capital costs are fixed, one-time expenses incurred on the purchase of buildings, construction and equipment. This may include funding for dedicated research facilities or equipment, refurbishments, or a share of capital assets commissioned for joint use (alongside patient care and/or training).

While the focus of the remit of this AMR call is to provide capital investment, some seed funding costs may also be included in the application. Seed funding will cover research costs of small research studies, for example, pilot or scoping studies. These pilot or scoping studies should aim to support further larger scale research projects, and are expected to leverage additional research funding, including from other public, charity and industry research funding sources to undertake full scale studies using the facilities acquired from the capital investment.


The funding is to support Research and Development activity and may not be used to support service delivery, for example, routine testing of samples.

The funding is not intended to meet NHS Support Costs or NHS treatment costs of research. The primary purpose of any equipment purchased with this funding should be for research activities and not used for frontline services or to inform patient care.

Funding will not be provided to support the costs of animal research.

Application Procedure

Applications should be submitted through the Research Management System (RMS) by 6 December 2018.

Any enquires should be made to or by phone on 0208 843 8048.

Addresses and contacts

Application forms can be found here.
Contact details:
National Institute for Health Research (NIHR) 
Room 132 
Richmond House 
79 Whitehall 
0208 843 8048